Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
1994-04-25
2001-07-17
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S512000
Reexamination Certificate
active
06262125
ABSTRACT:
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to novel polyamines having anti-neoplastic, anti-dirrheal, anti-peristaltic, gastrointestinal anti-spasmodic, and anti-viral, anti-retroviral, anti-psoriasis and insecticidal activities, as well as pharmaceutical compositions and methods of treatment based thereon and methods for their preparation.
In recent years, a great deal of attention has been focussed on the polyamines, e.g., spermidine, norspermidine, homospermidine, 1,4-diaminobutane (purtrescine) and spermine. These studies have been largely directed at the biological properties of the polyamines probably because of the role they play in proliferative processes. It was shown early on that the polyamine levels in dividing cells, e.g., cancer cells, are much higher than in resting cells. See Janne et al, A. Biochim. Biophys. Acta., Vol. 473, p. 241 (1978); Fillingame et al, Proc. Natl. Acad. Sci. U.S.A., Vol. 72, p. 4042 (1975); Metcalf et al, J. Am. Chem. Soc., Vol. 100, p. 2551 (1978); Flink et al, Nature (London), Vol. 253, p. 62 (1975); and Pegg et al, Polyamine Metabolism and Function, Am. J. Cell. Physiol., Vol. 243, pp. 212-221 (1982).
Several lines of evidence indicate that polyamines, particularly spermidine, are required for cell proliferation: (i) they are found in greater amounts in growing than in non-growing tissues; (ii) prokaryotic and eukaryotic mutants deficient in polyamine biosynthesis are auxotrophic for polyamines; and (iii) inhibitors specific for polyamine biosynthesis also inhibit cell growth. Despite this evidence, the precise biological role of polyamines in cell proliferation is uncertain. It has been suggested that polyamines, by virtue of their charged nature under physiological conditions and their conformational flexibility, might serve to stabilize macromolecules such as nucleic acids by anion neutralization. See Dkystra et al, Science, Vol. 149, p. 48 (1965); Russell et al, Polyamines as Biochemical Markers of Normal and Malignant Growth (Raven, N.Y., 1978); Hirschfield et al, J. Bacteriol., Vol. 101, p. 725 (1970); Hafner et al, J. Biol. Chem., Vol. 254, p. 12419 (1979); Cohn et al, J. Bacteriol., Vol. 134, p. 208 (1978); Pohjatipelto et al, Nature (London), Vol. 293, p. 475 (1981); Mamont et al, Biochem. Biophys. Res. Commun., Vol. 81, p. 58 (1978); Bloomfield et al, Polyamines in Biology and Medicine (D. R. Morris and L. J. Morton, eds., Dekker, N.Y., 1981), pp. 183-205; Gosule et al, Nature, Vol. 259, p. 333 (1976); Gabbay et al, Ann. N.Y. Acad. Sci., Vol. 171, p. 810 (1970); Suwalsky et al, J. Mol. Biol., Vol. 42, p. 363 (1969); and Liquori et al, J. Mol. Biol., Vol. 24, p. 113 (1968).
However, regardless of the reason for increased polyamine levels, the phenomenon can be and has been exploited in chemotherapy. See Sjoerdsma et al, Butterworths Int. Med. Rev.: Clin. Pharmacol. Thera., Vol. 35, p. 287 (1984); Israel et al, J. Med. Chem., Vol. 16, p. 1 (1973); Morris et al, Polyamines in Biology and Medicine; Dekker, N.Y., p. 223 (1981); and Wang et al, Biochem. Biophys. Res. Commun., Vol. 94, p. 85 (1980).
It is an object of the present invention to provide novel polyamines having a wide variety of biological activities.
It is another object of the present invention to provide novel compositions and methods of treatment and application based on the biological activities of the polyamines of the invention.
It is an additional object of the invention to provide novel methods for preparing the polyamines of the invention.
REFERENCES:
patent: 2267204 (1941-12-01), Kyrides
patent: 4321190 (1982-03-01), Costanzi et al.
patent: 4507321 (1985-03-01), Raisfeld
patent: 4591605 (1986-05-01), Ray
patent: 5091576 (1992-02-01), Bergeron
patent: 5109024 (1992-04-01), Prakash et al.
patent: 5242947 (1993-09-01), Cherksey et al.
Bergeron “Methods for the Selective Modification of Spermidine and its Homologues”, Acc. Chem. Res. 1986, 19, 105-113.*
Weinstock et al, Synthesis of New Polyamine Derivatives for Cancer Chemotherapeutic Studies, Journal of Pharmaceutical Sciences, vol. 70, No. 8, 1981.
Clarke Dennis P.
Lambkin Deborah C.
Miles & Stockbridge
University of Florida Research Foundation Inc.
LandOfFree
Sterically hindered tetraamines and method for their production does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sterically hindered tetraamines and method for their production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sterically hindered tetraamines and method for their production will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2524380